Ind-Swift Laboratories Ltd Share Price Today - Ind-Swift Laboratories Ltd Stock Price Live NSE/BSE

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB BSE: 532305

₹141.51

(-0.41%)

Sun, 22 Mar 2026, 03:07 am

MTF 5xInvest in Ind-Swift Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap11.57B

PE Ratio4.24

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Ind-Swift Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
1156.84
Net Profit
250.53
P/B
0.53
Sector P/E
31.86
P/E
2.30
EV/EBITDA
0.62
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
9.79
ROCE (Industry)
12.90
RONW (Industry)
12.30
ROE
0.14
ROCE
0.63
Debt/Equity
0.11
EPS (TTM)
5.80
Dividend Yield
0
Book Value
160.21
Interest Cover
3.01

Analysis

all

Pros

Ind-Swift Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.
Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
The level of debt compared to net worth has been reduced over the past 5 years (223.2% vs 188.2% today).
The tenure for the Ind-Swift Laboratories board of directors is about average.

Cons

Unable to calculate sustainability of dividends as Ind-Swift Laboratories has not reported any payouts.
Unable to evaluate Ind-Swift Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Ind-Swift Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Debt is not well covered by operating cash flow (13.1%, less than 20% of total debt).
Debt is not covered by short term assets, assets are 0.8x debt.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	39.50	39.50	40.94	40.94	42.00
FII	14.33	14.80	4.27	3.07	0.46
DII	0.68	0.68	0.91	0.91	0.94
Public	45.50	45.02	53.87	55.07	56.60
Government	0	0	0	0	0

Technical Analysis

RSI

54.64

MACD

3.76

50 DMA

126.99

200 DMA

107.87

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	226.01	180.26	162.80	134.51	117.05	88.76	43.01
Fibonacci	180.26	162.79	151.99	134.51	117.04	106.24	88.76
Camarilla	157.91	153.72	149.52	134.51	141.14	136.94	132.75

Pivots Level: Classic

+91.50

226.01

+45.75

180.26

+28.28

162.80

134.51

Pivot Point

LTP: 141.51

-17.47

117.05

-45.75

88.76

-91.50

43.01

Moving Average

SMAEMA

Period

Value

10-EMA
141.60
20-EMA
139.53
30-EMA
136.13
50-EMA
129.26
100-EMA
118.77
200-EMA
111.05

Announcement Date	Purpose	Action	Ex Date
31 Jan 2026	board-meetings	Quarterly Results, Nine Months Results
14 Nov 2025	board-meetings	Quarterly Results
25 Aug 2025	agm
20 Jan 2025	egm
02 Sept 2024	agm
24 Aug 2024	agm	Annual General Meeting	25 Sept 2024
28 Jun 2024	egm
06 Sept 2023	egm
31 Aug 2023	agm
22 Aug 2023	agm	Annual General Meeting	25 Sept 2023

Ind-Swift Laboratories Ltd

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Lupin Ltd

Torrent Pharmaceuticals Ltd

Ind-Swift Laboratories Ltd About

Ind-Swift Laboratories as an API manufacturer the Company has shifted its focus to formulation as its key business driver.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

N R Munjal

Employees

Contact

Website

http://www.indswiftlabs.com

investor@indswiftlabs.com, info@indswiftlabs.com

Phone

91-0172-5061850/2730920

Location

SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

Year	History
2013	R K Ummat was appointed as an Independent Director on the Board of the Company.
2014	Dr. Vinay Kumar Arora was appointed as an Independent Director.
2018	The company acquired KEC Bikaner Sikar Transmission Private Limited.
2020	Ind-Swift Labs tied up with a reputed generic player in the USA to launch generic Fexofenadine.
2021	Ind-Swift Laboratories Limited received the North India Best Employer Award.

Client Name	Order Side	QTY	Avg Price	Date
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	480857	133.19	06 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	480857	133.09	06 Feb 2026
WILSON HOLDINGS PRIVATE LIMITED	Sell	610000	72.02	22 May 2025
PRANAV JONEJA	Buy	614000	72.73	22 May 2025
WILSON HOLDINGS PRIVATE LIMITED	Sell	385685	71.8	16 May 2025
WILSON HOLDINGS PRIVATE LIMITED	Sell	531872	76.74	15 May 2025
WILSON HOLDINGS PRIVATE LIMITED	Sell	506000	70.87	08 May 2025
WILSON HOLDINGS PRIVATE LIMITED	Sell	727503	70.56	07 May 2025
MOHAMED IRFAN MOHAMED LATIF SHAIKH	Buy	16420	80.8	06 May 2025
MOHAMED IRFAN MOHAMED LATIF SHAIKH	Sell	364543	78.74	06 May 2025

Ind-Swift Laboratories Ltd News

Ind-Swift Labs Receives EcoVadis Silver Medal

Ind-Swift Laboratories Limited achieves EcoVadis Silver Medal for its Global Business Unit, placing the company among top 15% of organizations globally assessed for sustainability performance.

02 Mar 2026

stocks

Ind-Swift Forfeits ₹19.66 Cr from Lapsed Warrants

Ind-Swift Laboratories forfeited ₹19.66 crore after 65 lakh fully convertible warrants held by Saral Incorporated VCC Sub Fund 1 lapsed on February 28, 2026, following non-exercise within the 18-month period.

02 Mar 2026

co actions results

Ind-Swift Labs Allots 51 Lakh Equity Shares

Ind-Swift Laboratories completes preferential allotment of 51 lakh equity shares to Essix Biosciences through warrant conversion, raising paid-up capital to ₹86.71 crores.

24 Feb 2026

co actions results

Ind-Swift Labs Q3FY26 Monitoring Report Filed

Ind-Swift Laboratories submits Q3FY26 monitoring agency report for Rs. 314.60 crore preferential issue with no fund utilization during quarter and temporary fund transfer noted.

03 Feb 2026

stocks

Ind-Swift Labs Q3FY26 Net Profit Jumps to ₹1074 Lakhs

Ind-Swift Laboratories reported strong Q3FY26 results with net profit of ₹1074.18 lakhs vs loss of ₹86.19 lakhs in Q3FY25. Revenue grew 23% to ₹14948.10 lakhs. Board approved leadership restructuring effective Feb 1, 2026.

31 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800